iBio IBIO Stock News

iBio Inc (NYSEAMERICAN: IBIO) is headed up in the market again this morning. However, if you’re looking for press releases or SEC filings that explain the gains, you’re out of luck, there’s nothing out there. Nonetheless, there’s good reason for the excitement. 

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

IBIO Stock Heads For The Top

As mentioned above, iBio is making a move for the top in the market this morning, but the company hasn’t released any news. So, what’s the deal? Why are investors so excited about the stock?

The most recent news came 12 days ago, when the company announced that it signed an exclusive agreement with Planet Biotechnology. Under the terms of the agreement, IBIO has the worldwide rights to develop and commercialize a product known as ACE2-Fc. 

It is currently believed that the product will be an effective treatment option for patients with COVID-19. Of course, should the treatment prove to be effective, the implications for the company and its investors could be massive. But the new potential COVID-19 treatment candidate isn’t the only reason to be excited here. 

Let’s not forget that IBIO is working on, not 1, but 2 COVID-19 vaccine candidates. With one of these candidates, the company teamed up with a company known as CC-Pharming. This is key because CC-Pharming has already produced a vaccine for a cousin strain of the coronavirus that causes COVID-19. 

So What?

So, we have a company that has two COVID-19 vaccines and one treatment under development. What’s the big deal? Isn’t COVID-19 going away?

Sure, case counts are slowing down substantially. However, if history is any indication, COVID-19 is going to be a long-term problem for the healthcare community. The fact of the matter is that a big factor in the decline in case counts is heat. However, many scientists agree that when the winter months roll in, we’ll see a spike in cases, and that this cycle will continue for years to come. 

Moreover, the coronaviruses that cause the common cold have given us a lot of information on immunity to these types of viruses, which simply doesn’t last forever. 

Moreover, with the company’s FastPharming facility, it has the manufacturing power it needs to bring its potential vaccines and treatment to the masses. 

So, while cases are dying off and a vaccine seems to be nearly ready to hit the tape, it will likely be several years before COVID-19 is behind us, creating a runway with plenty of time and plenty of opportunity for IBIO and its investors ahead. 

The Bottom Line

The bottom line here is simple. Between 2 COVID-19 vaccines and a potential treatment option, there’s plenty of opportunity for IBIO to break into the COVID-19 space. When it does, the revenue that could be generated here is hard to ignore. As such, if you’re not paying attention to IBIO stock, you’re missing out. 

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Don’t Miss The Next Big Story

Join our free mailing list below to receive real-time news alerts!

Subscribe Today!

* indicates required


LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.